Amal Therapeutics SA

Amal Therapeutics SA is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Amal was incorporated on September 3rd 2012 and secured seed funding in February 2014 to establish and validate its technology platform. Boehringer Ingelheim Venture Fund led this initial financing round, with the High-Tech Gründerfond.

Over the past years, Amal Therapeutics has earned the recognition of several institutions and won several prizes or grants from different national and international funds including the Swiss commission for Technology and Innovation (CTI), the Eurostars programme, the Volkswirtschaftstiftung Swiss Foundation or the Fondation pour l’Innovation Technologique.

Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.